ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The U.S. subsidiary of Japanese drugmaker Eisai plans to invest $105 million to build a pharmaceutical production and formulation R&D facility at its existing site in Research Triangle Park, N.C. The new facility, which is set to open in 2009, will be dedicated to developing intravenous cancer drugs. The company expects the addition to bring 84 new jobs to the site over the next five years. Separately, Tokyo-based Astellas Pharma has bought Dynogen Pharmaceuticals' North Carolina-based research facility specializing in preclinical studies for genitourinary disorders.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter